백내장수술 후 발생한 건성안증후군에 대한 레바미피드 효과
The Effect of Topical Rebamipide 2% in Managing Dry Eye Following Cataract Surgery
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
목적: 백내장수술 후 발생한 건성안에서 레바미피드 2% 점안액의 임상 효과를 확인하고자 한다. 대상과 방법: 백내장수술 1주일째 건성안증후군을 선별하여 무작위로 레바미피드군과 대조군을 선정하여 레바미피드군에 레바미피드 점안액 2%를 투여하였으며, 레바미피드 점안액을 투여하지 않은 대조군과 비교하였다. 두 군에서 쉬르머검사, 눈물막파괴시간, 각결막염색, 눈물막삼투압, 눈물지질층두께, 안구표면질환지수 등의 안구건조증검사를 수술 1주일째, 1개월째, 2개월째에 시행하였다. 결과: 레바미피드군에서 눈물막파괴시간과 각막염색점수, 안구표면질환지수는 수술 후 1주일째에 비해 2개월째에 유의한 호전을 보였다(p=0.002, 0.014, 0.013). 레바미피드군에서 쉬르머검사와 눈물막삼투압검사, 눈물지질층두께는 유의한 변화를 보이지 않았다(1개월째: p=0.769, 0.394, 0.023; 2개월째: p=0.084, 0.917, 0.478). 수술 1개월째와 2개월째에, 레바미피드군이 대조군에 비해 눈물막파괴시간이 유의하게 길었으며(1개월째: p=0.007; 2개월째: p=0.000), 각막염색점수가 유의하게 낮았다(1개월째: p=0.000; 2개월째: p=0.000). 결론: 백내장수술 후 레바미피드 점안 시 눈물막파괴시간과 각막염색점수, 안구표면질환지수의 호전을 확인하였다. 백내장수술 후 발생하는 건성안증후군에서 레바미피드의 사용이 도움이 될 수 있다.
Abstract
Purpose: To evaluate the potential advantages of using topical rebamipide 2% to manage dry eye following cataract surgery. Methods: Patients who underwent cataract surgery (phacoemulsification and intraocular lens insertion) were evaluated for dry eye 1 week postoperatively. Randomly selected patients were divided into the rebamipide group, who received 2% rebamipide eye drops, and the control group, who did not receive rebamipide. Various dry eye-related tests, including Schirmer’s test, the tear break-up time (TBUT), ocular surface staining, tear film osmolarity, tear lipid layer thickness, and the ocular surface disease index (OSDI) were performed in both groups 1 week, and 1 and 2 months postoperatively. Results: In the rebamipide group, we observed significant improvement in TBUT, the ocular surface staining score, and OSDI at 2 months postoperatively, as compared to 1 week (p = 0.002, 0.014, and 0.013, respectively). Schirmer’s test, tear film osmolarity, and tear lipid layer thickness remained unchanged in the rebamipide group. Throughout the entire follow-up period, the rebamipide group had a significantly prolonged TBUT (1 month: p = 0.007, 2 months: p = 0.000), and lower ocular surface staining score (1 month: p = 0.000, 2 months: p = 0.000), as compared to the control. Conclusions: Following cataract surgery, the use of rebamipide eye drops produced improvements in TBUT, ocular surface staining scores, and OSDI. This suggests that rebamipide offers benefits in managing dry eye that can occur after cataract surgery.
참고문헌 (37)
- Craig JP, "TFOS DEWS II definition and classification report", Ocul Surf, 15, pp.276~283 (2017)
- Gipson IK, "Role of mucins in the function of the corneal and conjunctival epithelia", Int Rev Cytol, 231, pp.1~49 (2003)
- Miura M, "Prevalence and characteristics of dry eye disease after cataract surgery : a systematic review and meta-analysis", Ophthalmol Ther, 11, pp.1309~1332 (2022)
- Epstein SP, "Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells", J Ocul Pharmacol Ther, 25, pp.415~424 (2009)
- Hwang HB, "Phototoxic effects of an operating microscope on the ocular surface and tear film", Cornea, 33, pp.82~90 (2014)
- Arakawa T, "15th anniversary of rebamipide : looking ahead to the new mechanisms and new applications", Dig Dis Sci, 50(Suppl 1), pp.S3~S11 (2005)
- Kashima T, "Rebamipide ophthalmic suspension for the treatment of dry eye syndrome : a critical appraisal", Clin Ophthalmol, 8, pp.1003~1010 (2014)
- Takeji Y, "Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells", J Ocul Pharmacol Ther, 28, pp.259~263 (2012)
- Urashima H, "Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model", Cornea, 23, pp.613~619 (2004)
- Bron AJ, "Grading of corneal and conjunctival staining in the context of other dry eye tests", Cornea, 22, pp.640~650 (2003)
- Wolffsohn JS, "TFOS DEWS II diagnostic methodology report", Ocul Surf, 15, pp.539~574 (2017)
- Gipson IK, "Distribution of mucins at the ocular surface", Exp Eye Res, 78, pp.379~388 (2004)
- Kato K, "Conjunctival goblet cell density following cataract surgery with diclofenac versus diclofenac and rebamipide : a randomized trial", Am J Ophthalmol, 181, pp.26~36 (2017)
- Kimura K, "Protection of human corneal epithelial cells from TNF-α-induced disruption of barrier function by rebamipide", Invest Ophthalmol Vis Sci, 54, pp.2572~2760 (2013)
- Kinoshita S, "Rebamipide(OPC-12759)in the treatment of dry eye : a randomized, double-masked, multicenter, placebo-controlled phase II study", Ophthalmology, 119, pp.2471~2478 (2012)
- Koh S, "Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye", Cornea, 32, pp.1219~1223 (2013)
- Kinoshita S, "A randomized, multicenter phase 3 study comparing 2% rebamipide(OPC-12759)with 0. 1% sodium hyaluronate in the treatment of dry eye", Ophthalmology, 120, pp.1158~1165 (2013)
- Shimazaki J, "A prospective, randomized trial of two mucin secretogogues for the treatment of dry eye syndrome in office workers", Sci Rep, 7, pp.15210~ (2017)
- Cho YK, "Dry eye after cataract surgery and associated intraoperative risk factors", Korean J Ophthalmol, 23, pp.65~73 (2009)
- Oh T, "Changes in the tear film and ocular surface after cataract surgery", Jpn J Ophthalmol, 56, pp.113~118 (2012)
- Choi JH, "Effects of 0. 15% sodium hyaluronate on tear film and ocular surface disorders after vitrectomy surgery", Ann Optom Contact Lens, 20, pp.22~31 (2021)
- Khanal S, "Changes in corneal sensitivity and tear physiology after phacoemulsification", Ophthalmic Physiol Opt, 28, pp.127~134 (2008)
- Li XM, "Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery", Cornea, 26(9 Suppl 1), pp.S16~S20 (2007)
- Jung JW, "Meibomian gland dysfunction and tear cytokines after cataract surgery according to preoperative meibomian gland status", Clin Exp Ophthalmol, 44, pp.555~562 (2016)
- Lee AY, "Changes and possible role of neuropeptides in iatrogenic dry eye", Ann Optom Contact Lens, 21, pp.8~14 (2022)
- Kim MK, "Efficacy of strip meniscometry for dry eye syndrome diagnosis", J Korean Ophthalmol Soc, 57, pp.1521~1526 (2016)
- Portal C, "Ocular mucins in dry eye disease", Exp Eye Res, 186, pp.107724~ (2019)
- Toda I, "Dry eye with only decreased tear break-up time is sometimes associated with allergic conjunctivitis", Ophthalmology, 102, pp.302~309 (1995)
- "Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007)", Ocul Surf, 5, pp.108~152 (2007)
- Kaido M, "Visual function changes after punctal occlusion with the treatment of short BUT type of dry eye", Cornea, 31, pp.1009~1013 (2012)
- Takahashi Y, "Topical rebamipide treatment for superior limbic keratoconjunctivitis in patients with thyroid eye disease", Am J Ophthalmol, 157, pp.807~812 (2014)
- Chun YS, "Treatment of superior limbic keratoconjunctivitis with a large-diameter contact lens and botulium toxin A", Cornea, 28, pp.752~758 (2009)
- Tomlinson A, "Tear film osmolarity : determination of a referent for dry eye diagnosis", Invest Ophthalmol Vis Sci, 47, pp.4309~4315 (2006)
- Igarashi T, "Changes in tear osmolarity after cataract surgery", J Nippon Med Sch, 88, pp.204~208 (2021)
- Elksnis Ē, "Tear osmolarity after cataract surgery", J Curr Ophthalmol, 31, pp.31~35 (2019)
- Fukuoka S, "Increase in tear film lipid layer thickness after instillation of 3% diquafosol ophthalmic solution in healthy human eyes", Ocul Surf, 15, pp.730~735 (2017)
- Fukuoka S, "Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction : a randomized clinical study", Sci Rep, 9, pp.9091~ (2019)